앨버타 보건 서비스
Edmonton Metropolitan Region은 앨버타 보건 서비스(AHS) 본사로, 건강 관련 기업이 앨버타에서 사업을 시작하기 위해 찾는 전략적인 위치입니다. AHS는 캐나다 최초이자 최대의 지방 통합 보건 시스템으로, 400만 명 이상의 앨버타 주민에게 보건 서비스를 제공합니다. 연간 운영비용은 140억 달러를 초과합니다.
자연 제어 향상을 위한 생체 공학 신체(BLINC) 랩에 연구원과 임상의들이 모여 로봇과 기계 학습을 통해 인공 기관 관리를 발전시켰습니다. 주요 프로젝트로는 맞춤형 인공 기관 원형 제작, 인간의 움직임을 모방한 인공 기관 근전성 향상, 산업용 평가 도구 개발, 절단 등으로 상실된 인간의 능력을 회복하는 데 도움이 되는 기계 학습 활용 등이 있습니다.
Events
100 Years of the World’s Leading Diabetes Research
Read More
The Edmonton region’s pharmaceutical industry
12월 11, 2020
The Edmonton region has all the ingredients needed to attract investment into pharmaceutical manufacturing and research and development (R&D).
Read More
API grows pharma manufacturing capacity
11월 20, 2020
Applied Pharmaceutical Innovation (API) has passed an important milestone in securing the Edmonton Metropolitan Region’s place as a global player in the pharmaceutical manufacturing sector.
Read More
Canadian Innovators Take Rising COVID Cases Head-On
11월 12, 2020
Edmonton-based companies MACH32 and Andau Medical bring to market an aerosol containment device to reduce risk of COVID-19 exposure for healthcare personnel and patients.
Read More
Entos Pharmaceuticals Working with Applied Pharmaceutical Innovation to Enable In-house Development and Manufacturing Capability
10월 27, 2020
Entos Pharmaceuticals is working with Applied Pharmaceutical Innovation to enable in-house development and manufacturing capability
Read More
Alberta project validates first synthetic health dataset in province
10월 25, 2020
The health innovation community has one more approach towards increasing the timely and safe utilization of health data thanks to a research project co-sponsored by Health City and the Institute of Health Economics (IHE) in partnership with Alberta Innovates, Replica Analytics, and University of Alberta. Unique in Canada, this project was initiated to provide insight into the value and validity of synthetic (simulated) data in health services research. The promising results have been submitted for...
Read More
Entos Pharmaceuticals Awarded funding to Conduct Phase I Clinical Trial of COVID-19 DNA Vaccine
10월 23, 2020
Entos Pharmaceuticals (Entos), a healthcare biotechnology company developing nucleic acid medicines with its breakthrough proprietary Fusogenix drug delivery platform, is pleased to announce it is receiving advisory services and funding of up to $5M from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) as part of the Government of Canada’s continuing support for the development of domestic COVID-19 vaccine candidates.
Read More
Suite 100 - 10020 100 St.NW -T5J 0N5 Edmonton, AB
© Edmonton Global. All rights reserved
